tiprankstipranks
Trending News
More News >
Whitehawk Therapeutics, Inc. (WHWK)
:WHWK
Advertisement

Whitehawk Therapeutics (WHWK) AI Stock Analysis

Compare
486 Followers

Top Page

WHWK

Whitehawk Therapeutics

(NASDAQ:WHWK)

Rating:55Neutral
Price Target:
$2.00
▲(14.94% Upside)
Whitehawk Therapeutics has a low overall stock score primarily due to its financial instability and negative cash flows, which overshadow its strong balance sheet and relatively low valuation. Technical analysis suggests a neutral to slightly bearish outlook, further affecting the stock's attractiveness.
Positive Factors
Cash reserves
Cash and equivalents will settle at ~$185MM following completion of transactions, providing runway.
Financial transactions
The company has now completed divestiture of Aadi Subsidiary to Kaken for $102MM on top of closing a $100MM PIPE.
Negative Factors
Earnings report
Whitehawk reported a net loss of $0.67 per share for 4Q24, significantly higher than previously estimated.
Operational expenses
Research and development expenses and selling, general, and administrative expenses greatly exceeded earlier estimates.

Whitehawk Therapeutics (WHWK) vs. SPDR S&P 500 ETF (SPY)

Whitehawk Therapeutics Business Overview & Revenue Model

Company DescriptionWhitehawk Therapeutics (WHWK) is a biotechnology company focused on developing innovative therapeutics for autoimmune and inflammatory diseases. The company operates within the healthcare sector, leveraging its proprietary platform to identify and develop targeted therapies aimed at modulating immune responses. Whitehawk's core products include a pipeline of drug candidates designed to address various conditions, such as systemic lupus erythematosus and other related disorders, with an emphasis on enhancing patient outcomes through precision medicine.
How the Company Makes MoneyWhitehawk Therapeutics generates revenue primarily through several key channels, including grant funding, strategic partnerships, and potential licensing agreements. The company may receive funding from government or private grants aimed at supporting research and development of its therapies. Additionally, Whitehawk seeks to establish collaborations with larger pharmaceutical companies, which can provide upfront payments, research funding, and milestone payments tied to the development and commercialization of its drug candidates. Ultimately, the company's revenue model is heavily reliant on successful clinical trials leading to regulatory approvals, after which it may generate income through product sales or royalties from its partnered therapies.

Whitehawk Therapeutics Earnings Call Summary

Earnings Call Date:Aug 07, 2025
(Q4-2024)
|
% Change Since: 6.10%|
Next Earnings Date:Nov 05, 2025
Earnings Call Sentiment Positive
The earnings call reflects a positive sentiment with significant strategic transformations, a promising pipeline of ADC therapies, and strong financial positioning. However, there are concerns about increased R&D expenses and net losses, which are common in early biotech transitions.
Q4-2024 Updates
Positive Updates
Transformation and Strategic Transactions
Whitehawk Therapeutics was launched from Aadi Biosciences, including in-licensing 3 ADCs from Wuxi Biologics, divestiture of FYARRO to Kaken Pharmaceuticals, and $100 million pipe financing, approved by stockholders.
Advanced ADC Platform
Whitehawk is rapidly progressing a multi-asset portfolio of advanced ADC therapy, leveraging a platform with minimal off-target toxicity, greater stability, and higher therapeutic index compared to first-generation predecessors.
Financial Position
Ended 2024 with $47.2 million in cash and expect $170-$180 million after transactions, funding operations into 2028.
FYARRO Sales Growth
FYARRO net product sales were $7.2 million for Q4, representing 14% growth over the prior year quarter. Full-year sales were $26 million, an increase of 7% over 2023.
Negative Updates
Increased R&D Expenses
Research and development expenses for Q4 increased to $14.3 million compared to $12.8 million in the prior year quarter, primarily due to in-process R&D expenses related to the acquired ADC programs.
Net Loss
Net loss for the fourth quarter was $18.3 million compared to $16.3 million in the fourth quarter of 2023. Net loss for the year was $63.7 million compared to $65.8 million in the prior year.
Company Guidance
In the earnings call for the fourth quarter and full year 2024, Whitehawk Therapeutics provided guidance on their transformative shift from Aadi Biosciences to an ADC-focused company. The key metrics highlighted include a $100 million PIPE financing and the divestiture of FYARRO, which resulted in a financial position of $170 million to $180 million in cash and equivalents, expected to fund operations into 2028. The company reported FYARRO net product sales of $7.2 million for the fourth quarter, marking a 14% increase from the previous year, and $26 million for the full year, a 7% rise from 2023. Research and development expenses increased to $14.3 million for the quarter and $51 million for the year, primarily due to ADC program acquisitions. Whitehawk plans to file three Investigational New Drug (IND) applications within 15 months for their ADC candidates, targeting PTK7, MUC16, and SEZ6, with anticipated Phase 1 trials in several high-potential cancer indications.

Whitehawk Therapeutics Financial Statement Overview

Summary
Whitehawk Therapeutics demonstrates revenue growth and a stable financial structure, yet struggles with profitability and cash flow challenges. While the balance sheet shows a strong equity position, the ongoing net losses and negative cash flow could pressurize future operations. The company needs to address operational inefficiencies to improve its financial health.
Income Statement
45
Neutral
The company's income statement reveals consistent revenue growth over the years, but profitability remains a significant issue. Gross and net profit margins are negative, indicating high operational costs relative to revenue. The EBIT and EBITDA margins are also negative, highlighting operational inefficiencies and challenges in reaching profitability. Despite revenue growth, the persistent net losses and high operating expenses present financial risks.
Balance Sheet
40
Negative
The balance sheet reflects a relatively strong equity position with a positive equity ratio. However, the company carries substantial liabilities, which, coupled with negative equity in earlier years, pose long-term risks. The debt-to-equity ratio is low, suggesting manageable debt levels. Nonetheless, the negative return on equity due to recurring net losses remains a concern.
Cash Flow
50
Neutral
Cash flow analysis shows significant operating cash outflows, consistent with the company's lack of profitability. However, the company has maintained negative free cash flow, which could strain liquidity in the absence of financing. The operating cash flow to net income ratio is unfavorable, indicating cash flow challenges. Despite these issues, the company has managed to maintain cash reserves through financing activities, mitigating immediate liquidity risks.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue25.98M24.35M15.22M1.12M14.58M
Gross Profit-28.07M-27.38M-18.78M-18.55M-428.00K
EBITDA-64.63M-71.76M-58.80M-36.96M-2.54M
Net Income-63.69M-65.77M-60.51M-110.09M-3.48M
Balance Sheet
Total Assets70.32M132.42M184.24M157.91M18.82M
Cash, Cash Equivalents and Short-Term Investments47.24M108.84M172.56M148.99M4.46M
Total Debt833.00K1.27M1.66M605.00K10.26M
Total Liabilities17.84M27.23M25.86M21.50M31.26M
Stockholders Equity52.48M105.19M158.38M136.41M-12.43M
Cash Flow
Free Cash Flow-61.20M-63.63M-50.08M-22.47M-12.70M
Operating Cash Flow-59.55M-59.66M-49.64M-22.42M-12.70M
Investing Cash Flow25.20M83.21M-132.89M25.15M0.00
Financing Cash Flow130.00K326.00K72.62M141.80M1.19M

Whitehawk Therapeutics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.74
Price Trends
50DMA
1.89
Negative
100DMA
1.81
Negative
200DMA
2.18
Negative
Market Momentum
MACD
-0.04
Positive
RSI
40.54
Neutral
STOCH
17.98
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For WHWK, the sentiment is Negative. The current price of 1.74 is below the 20-day moving average (MA) of 1.90, below the 50-day MA of 1.89, and below the 200-day MA of 2.18, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 40.54 is Neutral, neither overbought nor oversold. The STOCH value of 17.98 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for WHWK.

Whitehawk Therapeutics Risk Analysis

Whitehawk Therapeutics disclosed 101 risk factors in its most recent earnings report. Whitehawk Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Whitehawk Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
55
Neutral
$83.38M11.8017.69%16.51%
54
Neutral
€4.12B12.84-53.01%2.57%13.59%-29.69%
52
Neutral
$106.62M-60.25%255.31%-141.39%
45
Neutral
$65.92M-88.03%-21.28%36.26%
43
Neutral
$89.05M-456.32%0.13%
36
Underperform
$113.12M-76.21%23.55%
33
Underperform
$155.23M43.604.14%33.97%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
WHWK
Whitehawk Therapeutics
1.76
0.41
30.37%
VERU
Veru
0.45
-0.36
-44.44%
MGNX
MacroGenics
1.69
-1.76
-51.01%
BDTX
Black Diamond Therapeutics
2.73
-2.11
-43.60%
SRZN
Surrozen
10.40
3.30
46.48%
TNYA
Tenaya Therapeutics
0.70
-1.98
-73.88%

Whitehawk Therapeutics Corporate Events

Executive/Board ChangesShareholder Meetings
Whitehawk Therapeutics Elects Directors at Annual Meeting
Neutral
Jun 13, 2025

Whitehawk Therapeutics, Inc. held its annual meeting of stockholders on June 11, 2025, where 61% of the voting power was represented. During the meeting, three Class II directors were elected, executive compensation was approved on an advisory basis, and BDO USA, P.C. was ratified as the independent accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (WHWK) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Whitehawk Therapeutics stock, see the WHWK Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 29, 2025